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Abstract
Background: A close association between narcolepsy and the Human Leukocyte Antigen (HLA)-DQB1*0602 allele suggests
the involvement of the immune system, or possibly an autoimmune process. We investigated serum IgG levels in
narcolepsy.
Methodology/Principal Findings: We measured the serum total IgG levels in 159 Japanese narcolepsy-cataplexy patients
positive for the HLA-DQB1*0602 allele, 28 idiopathic hypersomnia patients with long sleep time, and 123 healthy controls (the
HLA-DQB1*0602 allele present in 45 subjects). The serum levels of each IgG subclass were subsequently measured. The
distribution of serum IgG was significantly different among healthy controls negative for the HLA-DQB1*0602 allele
(11.6663.55 mg/ml), healthy controls positive for the HLA-DQB1*0602 allele (11.4563.43), narcolepsy patients (9.6763.38),
and idiopathic hypersomnia patients (13.8163.80). None of the following clinical variables, age, disease duration, Epworth
Sleepiness Scale, smoking habit and BMI at the time of blood sampling, were associated with IgG levels in narcolepsy or
idiopathic hypersomnia. Furthermore we found the decrease in IgG1 and IgG2 levels, stable expression of IgG3, and the
increaseinthe proportionofIgG4innarcolepsypatients withabnormallylowIgGlevels. Theincrease inthe proportion of IgG4
levels was also found in narcolepsy patients with normal serum total IgG levels. Idiopathic hypersomnia patients showed a
different pattern of IgG subclass distribution with high IgG3 and IgG4 level, low IgG2 level, and IgG1/IgG2 imbalance.
Conclusions/Significance: Our study is the first to determine IgG abnormalities in narcolepsy and idiopathic hypersomnia
by measuring the serum IgG levels in a large number of hypersomnia patients. The observed IgG abnormalities indicate
humoral immune alterations in narcolepsy and idiopathic hypersomnia. Different IgG profiles suggest immunological
differences between narcolepsy and idiopathic hypersomnia.
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Introduction
Narcolepsy is a chronic sleep disorder characterized by
excessive daytime sleepiness and cataplexy [1]. Narcolepsy bears
a remarkable association with Human Leukocyte Antigen (HLA)-
DQB1*0602 allele, suggesting that an autoimmune process
underlies the pathophysiology of narcolepsy [2]. Several studies
based on the autoimmune hypothesis have been conducted on
possible narcolepsy-related antigens or the screening of novel
autoantibodies against the hypothalamus [3], [4], [5], [6], [7], [8],
[9], [10]. Thus far, however, no studies have furnished notable
results for obtaining autoantibodies related to narcolepsy.
Recently, Jackson et al. showed that immunoglobulin G (IgG),
which was purified and concentrated from narcolepsy patients,
bound to membrane proteins and modified colon function [11].
Potential reasons why conventional methods fail to detect such
functional autoantibodies are the denaturation of target antigens,
extremely low concentrations of high affinity antibody, and low
levels of initial total IgG level in the serum of narcolepsy patients.
Our previous studies for autoantibody screening showed that the
autoantibody indices of narcolepsy patients were generally low and
sometimes below the mean minus 2SD of healthy controls [5],
[10]. This finding is in line with the last possible reason for the
failure in autoantibody detection. Furthermore, a case of common
variable immunodeficiency syndrome (IgG2 and IgG4 deficiency)
has been reported after the onset of narcolepsy [12]. Thus, high-
dose intravenous immunoglobulins (IVIg), which have been shown
to decrease the frequency and severity of cataplexy in some
narcolepsy patients [13], might be effective not only through the
assumed neutralization by anti-idiotypic autoantibody but through
supplementation of low IgG. In the present study, we measured
the serum levels of total IgG and four IgG subclasses in
narcolepsy-cataplexy patients and compared these values with
those in healthy controls and in patients with typical idiopathic
hypersomnia with long sleep time.
Materials and Methods
This research was approved by the ethics committees of the
Neuropsychiatric Research Institute (Tokyo, Japan) and the Tokyo
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consents were obtained from all participants. All the patients
were clinically diagnosed at the Neuropsychiatric Research
Institute according to the diagnostic criteria defined in the
International Classification of Sleep Disorders, second edition
[1]. Five mL of blood was drawn and the sera were stored at
280C until use at the Tokyo Institute of Psychiatry or at the
Neuropsychiatric Research Institute. Clinical data relating to sleep
habits were obtained and used for analysis. Healthy subjects were
excluded from the study if they reported excessive daytime
sleepiness or any signs of immunological abnormalities in the
questionnaire collected at the time of blood collection.
Patient demographic data are summarized in Table 1. All the
narcolepsy patients had definite cataplexy and were positive for
HLA-DQB1*0602 allele. Sera from 159 narcolepsy-cataplexy
patients, 28 patients with idiopathic hypersomnia with long sleep
time, and 123 healthy controls (78 negative and 45 positive for
HLA-DQB1*0602 allele; they were hereinafter referred to as HLA-
negative controls and HLA-positive controls, respectively) were
examined. HLA typing for HLA-DRB1 and DQB1 loci were
performed for all subjects at the NPO HLA Laboratory (Kyoto,
Japan) or by the Wakunaga Pharmaceutical Company (Hir-
oshima, Japan). We analyzed potential relationships of the
following clinical data with the IgG level: age, sex, disease
duration, body mass index (BMI), smoking habits and Epworth
Sleepiness Scale (ESS) obtained at the time of blood collection,
and past history of autoimmune disorders. Since smoking is shown
to be associated with decreased level of IgG [14], we analyzed the
effect of smoking habits in details.
To examine the details of total IgG abnormality especially in a
subgroup of narcolepsy patients with abnormally low IgG level, we
subsequently selected 67 samples from 245 initial experiments and
measured the IgG subclass in 23 narcolepsy patients (total IgG
levels normal in 13 patients and abnormally low in 10), 14 HLA-
negative controls, 13 HLA-positive controls, and 17 idiopathic
hypersomnia patients.
The serum IgG levels were measured using the Easy-Titer
Human IgG (H+L) Assay Kit (Pierce Biotechnology Inc., IL) based
on monodispersed polystyrene beads. The beads are coated with
anti-human IgG and absorb light at 340 and 405 nm. Once the
anti-human IgG on the beads bind to serum IgG, the beads
aggregate and cause a decrease in the light absorption. The normal
range oftheserumtotalIgGmeasuredbythiskitis5.5–22.0 mg/ml
according to the manufacturer’s instructions. The serum total IgG
levels below or above this range are considered to be abnormal.
Human IgG molecules are subdivided into four classes: IgG1–4.
The low level of each subclass or a combination of these subclasses
is found in congenital or secondary immunodeficiency diseases
[15]. Therefore, we next measured the serum levels of four IgG
subclasses to examine the characteristics of IgG subclass profiles
especially in narcolepsy patients with abnormally low total IgG
level. These serum levels were compared among 10 narcolepsy
patients with low serum IgG levels, 13 age-matched narcolepsy
patients with normal serum IgG levels, 13 age-matched HLA-
negative controls, 14 age-matched HLA-positive controls (all the
controls showed normal total IgG level), and 17 idiopathic
hypersomnia patients (two of which were positive for HLA-
DQB1*0602 allele). The serum level of each IgG subclass was
determined using the human IgG subclass profile ELISA kit
(Invitrogen, Carlsbad, CA) based on a sandwich-type ELISA
method.
The proportion of each IgG subclass in each subject was
calculated and expressed as a ratio of the value to the total of
IgG1, IgG2, IgG3, and IgG4. Since the IgG subclasses were
not normally distributed, we followed the recommendation for
setting normal ranges [16] and determined the normal range of
each IgG subclass as the mean 6 2SD in the 13 HLA-negative
controls.
Distribution of the total IgG and IgG subclass levels among
groups of narcolepsy, idiopathic hypersomnia, and healthy
controls was compared using ANOVA and the Mann-Whitney
U test. Significance levels are set at p,0.0125 for total IgG and
p,0.01 for each IgG subclass after Bonferroni correction for
multiple comparisons. We assessed the effect of age, disease
duration, ESS, and BMI on total IgG levels using multivariate
regression analysis. We also compared the distribution of serum
total IgG levels according to sex difference and smoking habit by
using the Mann-Whitney U test.
Results
The mean total IgG level showed significant differences among
groups: it was lower in narcolepsy-cataplexy patients (mean 6 SD:
9.6763.38, range: 3.26–24.36 mg/ml, p,0.00005) and higher in
idiopathic hypersomnia patients (13.8163.80, 7.75–22.80 mg/ml,
p,0.01) than in HLA-negative controls (11.6663.55, 5.59–
22.26 mg/ml) (Fig. 1, Table 1). The mean total IgG level was
also lower in narcolepsy-cataplexy patients (p,0.005) and higher
in idiopathic hypersomnia patients with long sleep time (p,0.001)
than in HLA-positive controls (11.4563.43, 7.23–21.15 mg/ml).
Table 1. Profile of the subjects.
n
Age
(years, mean 6 SD)
Sex,
no. male/
no. female IgG concentration (mg/ml)
range mean 6 SD
below normal
range
above normal
range
Healthy controls 123 41.18611.69 69/54 5.59–22.26 11.5863.49 0 1
HLA-DQB1*0602 negative 78 42.19612.22 49/29 5.59–22.26 11.6663.55 0 1
HLA-DQB1*0602 positive 45 39.35610.56 20/25 7.23–21.15 11.4563.43 0 0
Narcolepsy with cataplexy 159 46.63617.30 96/63 3.26–24.36 9.6763.38* 12 1
Idiopathic hypersomnia 28 27.18610.95* 11/17 7.75–22.80 13.8163.80* 0 3
The Mann– Whitney U-test was used to compare IgG concentration among patient groups and healthy controls.
*The mean values were significantly different from healthy controls negative for HLA-DQB1*0602 allele at p,0.05.
doi:10.1371/journal.pone.0009555.t001
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samples from HLA-positive controls with high IgG levels were
outliers as compared to the remaining 43 HLA-positive controls.
After omitting these two outliers, we still observed significant
differences in the mean total IgG level between narcolepsy patients
and HLA-positive controls (p,0.005). One healthy control, one
narcolepsy patient, and three idiopathic hypersomnia patients
showed abnormally high serum total IgG levels above the normal
range. Instead, 12 male narcolepsy patients showed abnormally
low total IgG levels.
None of the following clinical variables, age, disease duration,
ESS score, smoking habit, and BMI at the time of blood sampling,
were independently associated with IgG levels in narcolepsy
patients and idiopathic hypersomnia patients. The serum total IgG
level in smokers was significantly lower than that in non-smoker
among healthy controls (p,0.05), confirming the previous report
[14] (HLA-negative controls without smoking: 12.8263.61, HLA-
negative controls with smoking; 10.6162.41, HLA-positive
controls without smoking: 11.7263.18, HLA-positive controls
with smoking; 9.6762.23) (Figure S1). Epidemiological study
suggests that narcolepsy patients had increased risk of passive
smoking [17]. However, the decrease in the serum total IgG level
in narcolepsy patients was observed regardless of smoking habits,
and there were no significant difference between smoking group
and non-smoking group in narcolepsy patients (9.2262.80 and
9.9563.21, respectively). Idiopathic hypersomnia patients (all non-
smokers) showed marginally high total IgG level (14.9764.07)
when compared with non-smoking controls (p=0.053). Data
regarding the smoking habit were available in 4 of 12 narcolepsy
patients with abnormally low total IgG level; one was non-smoker
and the others were smokers. In non-smoking controls, we found a
sex difference in total IgG level according to the HLA-status; the
mean total IgG level of HLA-positive male controls was marginally
low (10.4862.21) compared to those of HLA-negative male
controls (13.0963.56) (p=0.031), while no significant difference
was found between HLA-positive (12.3063.45) and negative
(12.2563.81) female controls (p=0.451). We also analyzed the
effect of psycho-stimulant medication on the low total IgG level.
Four of the 12 narcolepsy patients with low IgG levels were un-
medicated at the time of blood sampling. No differences were
observed in the serum total IgG levels between 8 medicated and 4
un-medicated narcolepsy patients with low IgG levels.
We next analyzed the serum levels of four IgG subclasses in 23
narcolepsy patients (total IgG levels were low in 10 patients and
within the normal range in 13), 27 healthy controls (13 HLA-
negative and 14 HLA-positive) and 17 idiopathic hypersomnia
patients. The results of mean IgG1, IgG2, IgG3, and IgG4 levels,
the IgG1/IgG2 ratio, and the estimated normal range determined
from 13 HLA-negative controls are summarized in Table 2. The
mean percentage of each IgG subclass in the summation of the
four IgG subclasses and the calculated reference ranges are
summarized in Table 3.
The distribution of each IgG subclass showed significant or
marginally significant differences among 5 groups by analysis of
variance, therefore we studied the details to clarify the character-
istics of narcolepsy patients with low total IgG levels and idiopathic
hypersomnia patients with long sleep time as follows;
IgG1: The mean IgG1 levels were significantly lower in
narcolepsy patients with low total IgG levels than in HLA-
negative controls (p,0.005), HLA-positive controls (p,0.01),
narcolepsy patients with normal total IgG levels (p,0.01), and
idiopathic hypersomnia patients (p,0.005) (Table 2, Fig. 2). Five
narcolepsy patients with low total IgG levels and two idiopathic
hypersomnia patients had abnormal IgG1 levels (Fig. 2).
IgG2: The mean IgG2 levels in idiopathic hypersomnia patients
(p=0.011) tended to decrease, and those in the subgroup of
narcolepsy patients with low total IgG levels tended to decrease
(p=0.026) compared with the mean IgG2 levels in HLA-negative
Figure 1. Serum total IgG level. Each dot corresponds to the serum IgG level (mg/ml) in each subject. Dotted lines indicate the normal range. The
normal range is set at 5.5–22.0 mg/ml according to the manufacturer’s instructions. Horizontal lines and squares indicate the mean 6 SD of four
groups. Outlined-dots indicate the median of four groups.
doi:10.1371/journal.pone.0009555.g001
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idiopathic hypersomnia patient presented low IgG2 levels below
the normal range. The mean proportion of IgG2 in idiopathic
hypersomnia patients was significantly lower than that in HLA-
negative controls (Table 3).
IgG1/IgG2 ratio: The mean IgG1/IgG2 ratios tended to
increase in idiopathic hypersomnia patients as compared with
those in HLA-negative controls (p=0.0101) (Table 2, Fig. 4). Two
HLA-positive controls, five narcolepsy patients, and four idio-
pathic hypersomnia patients showed abnormal IgG1/IgG2 ratios.
IgG3: The mean IgG3 levels tend to be higher in idiopathic
hypersomnia patients than in HLA-negative controls (p=0.016),
HLA-positive controls (p=0.029), and narcolepsy patients with
low IgG level (p=0.0105) (Table 2, Fig. 5). Abnormally high IgG3
levels were found in three narcolepsy patients and seven idiopathic
hypersomnia patients. The mean proportion of IgG3 significantly
increased in idiopathic hypersomnia patients (p,0.01) and tended
to be higher in the narcolepsy patients with normal IgG levels
(p=0.026) than in HLA-negative controls (Table 3).
IgG4: Narcolepsy patients with normal IgG levels tended to
have higher IgG4 levels as compared to HLA-positive controls
(p=0.020) (Table 2, Fig. 6). The mean IgG4 levels were relatively
higher in narcolepsy patients and idiopathic hypersomnia patients,
but these differences were not statistically significant (Table 2).
Abnormal IgG4 levels were found in one HLA-positive control, 10
narcolepsy patients, and 7 idiopathic hypersomnia patients. The
mean proportion of IgG4 significantly increased in both
narcolepsy patients and idiopathic hypersomnia patients regardless
of total IgG levels as compared with that in healthy controls
(Table 3)
Discussion
Our study is the first to determine IgG abnormalities in
narcolepsy and idiopathic hypersomnia by measuring the serum
IgG levels in a large number of hypersomnia patients. Decrease in
the serum total IgG levels and stable IgG3 level were found in a
subgroup of narcolepsy patients with abnormally low total IgG
levels. The elevated proportion of IgG4 subclass was a common
finding in narcolepsy patients regardless of serum total IgG levels.
On the other hand, elevated total IgG levels, IgG3, IgG4, and
IgG1/IgG2 ratio and low IgG2 level were found in idiopathic
hypersomnia patients. Our data indicated a significant increase in
the IgG1/IgG2 ratio in idiopathic hypersomnia patients, suggest-
ing a Th1 involvement in idiopathic hypersomnia. Different IgG
profiles between these two hypersomnias indicate immunological
differences, which might be utilized as a supplemental marker for
the differential diagnosis of the two hypersomnias.
Sleep alterations found in narcolepsy and idiopathic hypersom-
nia, such as disturbed or excessive sleep, could mediate the changes
found in narcolepsy or idiopathic hypersomnia. In this case, the
immune alterations reported here would be the consequence rather
Table 2. Four IgG subclasses (mg/ml).
n IgG1 IgG2 IgG1/IgG2 ratio IgG3 IgG4
Healthy controls
HLA-DQB1*0602 negative 13 6.7661.23 4.0761.30 1.8060.58 0.3060.11
{ 0.4960.19
HLA-DQB1*0602 positive 14 6.2361.27 3.1361.12 2.3161.24 0.3360.10
{ 0.4160.31
¡
Narcolepsy
with normal range of IgG 13 6.1561.06 3.7361.56 1.9660.90 0.4060.14 0.8260.50
with low IgG levels 10 4.6562.42* 2.7161.24
{ 2.4062.11 0.2860.16
{ 0.5960.63
Idiopathic hypersomnias 17 7.3962.81 2.9561.11
{ 2.6760.93
{ 0.5560.34
{ 0.9261.12
Normal range estimated 4.30–9.22 1.46–6.68 0.65–2.96 0.07–0.55 0.11–0.88
*P,0.01 amongst healthy controls negative, positive for HLA-DQB1*0602 allele, narcolepsy with normal range of IgG and idiopathic hypersomnias.
{The Value showed a raising/declining tendency against healthy controls negative for HLA-DQB1*0602 allele (P,0.03).
{P,0.03 against idiopathic hypersomnias.
¡P,0.03 against narcolepsy patients with normal range of IgG.
doi:10.1371/journal.pone.0009555.t002
Table 3. The proportion of each IgG subclass in total IgG (%).
n IgG1 IgG2 IgG3 IgG4
Healthy controls
HLA-DQB1*0602 negative 13 58.5565.79 34.4866.68 2.6861.05 4.3061.41
HLA-DQB1*0602 positive 14 61.8769.54 30.7068.53 3.3861.31 4.0662.86
Narcolepsy
with normal range of IgG 13 56.7769.79 32.5569.10 3.6761.23* 7.0663.92
with low IgG levels 10 56.60616.71 33.29613.95 3.3561.61 6.8366.96
Idiopathic hypersomnias 17 62.8565.61 25.6666.77** 4.7962.93** 6.7064.70
Normal range estimated 46.97–70.14 21.12–47.84 0.57–4.78 1.47–7.12
*P,0.03,
**P,0.01 against healthy controls negative for HLA-DQB1*0602 allele.
doi:10.1371/journal.pone.0009555.t003
IgG Abnormality in Hypersomnia
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9555than the cause of the phenotype. Indeed, sleep restriction or
deprivation has immunomodulatory effects, and alters serum IgG
levels [18], [19]. Similarly, acute stress shows immune-enhancing
and chronic stress provokes immune-suppression [20], [21]. A
decline of sleep quality with chronic stresses induced by nocturnal
sleep fragmentation and prolonged excessive daytime sleepiness
might lead to the decrease in the serum total IgG levels in our
narcolepsy patients.
A recent report found high titers of anti-streptolysin O antibody
in narcolepsy patients within 3 years of disease onset [22]. Our
findings of IgG alteration might underlie an increased suscepti-
bility to specific infectious diseases. However we could not find any
difference in disease duration between narcolepsy patients with
and without abnormally low total IgG levels (27.3 years 616.5,
range: 9–48 years vs. 27.0615.8, range: 1–52 years) and four
narcolepsy patients within 3 years of disease onset showed no
increased/decreased IgG levels. The observed IgG abnormality
seemed to be disease independent and less likely the result of a
putative infection.
In contrast to narcolepsy patients, idiopathic hypersomnia
patients were likely to have increased slow-wave sleep [23]. Recent
report showed that nocturnal sleep increases the percentage of
Figure 2. Serum IgG1 level. Each dot corresponds to the serum IgG subclass level (mg/ml) in each subject. Dotted lines indicate the mean 6 2SD
of healthy control subjects without DQB1*0602 as normal range. Horizontal lines and squares indicate the mean 6 SD of five groups.
doi:10.1371/journal.pone.0009555.g002
Figure 3. Serum IgG2 level. The definitions of dots, dotted lines, horizontal lines, and squares are provided in the legend for Figure 2.
doi:10.1371/journal.pone.0009555.g003
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percentage of IL-10 producing monocytes [24]. As one possibility,
the increase in nocturnal sleep-associated predominance of type
I cytokines might result in the augmentation of total IgG and
the Th1 predominance in idiopathic hypersomnia patients.
Several patients with symptoms similar to idiopathic hypersomnia
were reported to have neural-specific anti-AQP4 antibody
[25], [26], [27], and this organ-specific autoimmunity might be
compatible with our findings of a Th1 involvement in idiopathic
hypersomnia.
In narcolepsy patients, total IgG levels decreased, while the
IgG3 subclass level stayed unchanged. IgG3 subclass appears first
in the course of infection before other subclasses, probably
reflecting the genomic position of gamma genes for the constant
region in the immunoglobulin heavy chain locus. We speculate
that the class switch from IgG3 to other IgG subclass in somatic
Figure 4. IgG1/IgG2 ratio. Dots correspond to the IgG1/IgG2 ratio in each subject. The definitions of dotted lines, horizontal lines, and squares are
provided in the legend for Figure 2.
doi:10.1371/journal.pone.0009555.g004
Figure 5. Serum IgG3 level. Definitions of dots, dotted lines, horizontal lines, and squares are provided in the legend for Figure 2.
doi:10.1371/journal.pone.0009555.g005
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narcolepsy. This dysregulation in the process of immunoglobulin
maturation could also explain the decrease in IgG1 and IgG2 in
narcolepsy with abnormally low total IgG levels. An immuno-
globulin switch-like sequence was reported as a tight linkage
marker for canine narcolepsy gene 1 [28]. It would be worthwhile
to reanalyze human mu-switch region in detail, because the
previous negative report of association using restriction fragment
length polymorphism analysis might not examine the locus
completely [29]. We observed elevated IgG4 ratio to total IgG
in narcolepsy patients regardless of the total IgG levels. IgG4
abnormalities could be detected more efficiently when we used the
proportion of IgG4. Two narcolepsy patients showed low IgG4
levels along with a marked reduction in IgG1 and IgG2. General
immune-suppression may have occurred in these patients, similar
to the case report of a narcolepsy patient who developed common
variable immunodeficiency syndrome after the onset of narcolepsy
[12]. However, these two patients took a typical clinical course of
narcolepsy without severe immunological comorbid symptoms.
The marked decrease in IgG observed in these two patients might
be subclinical or somehow compensated.
Although no significant sex difference was observed in the mean
total IgG levels in our study, which is consistent with results of a
previous study [14], only male narcolepsy patients had abnormally
low total IgG levels. We could not explain the reason for this
gender difference. The mean total IgG level was marginally low in
male HLA-positive controls compared with male HLA-negative
controls (all: p=0.016, limited to non-smokers: p=0.032), while
no difference was found in female controls according to HLA-
DQB1*0602-positivity (p=0.394). The combination of male sex
and HLA-DQB1*0602 allele might bring forward the decrease of
IgG level and sometimes form a subgroup of narcolepsy with
abnormally low total IgG levels.
We could not match the possible confounding factors including
age, sex, and HLA allele on the analysis of idiopathic hypersomnia
patients with long sleep time, since the prevalence of idiopathic
hypersomnia with long sleep time is low, estimated as only
2.0–4.1% of narcolepsy-cataplexy and female predominance were
suggested [30], [31], [32]. Among these possible confounding
factors, no sex differences were reported on total IgG levels [14].
As for the age, IgM and IgG levels were reported to be lower in
children below 16 years compared with adults in general
population [33]. However all our subjects were above 16 years
except for two idiopathic hypersomnia patients, and these two
patients showed normal total IgG levels. Thus the difference in age
is not likely the cause of observed high levels of total IgG in
idiopathic hypersomnia. As for the HLA allele contribution on IgG
level, two idiopathic hypersomnia patients positive for the HLA-
DQB1*0602 allele were examined separately, but did not show
increased/decreased IgG levels compared to those negative for the
HLA allele. Studies using larger number of samples positive for
HLA-DQB1*0602 allele would be required to distinguish the HLA
allele related effect and disease specific increase of IgG levels in
idiopathic hypersomnia.
It would be necessary to evaluate the IgG levels in patients with
narcolepsy without cataplexy, which was reported to have lower
HLA association than narcolepsy-cataplexy and might have
different IgG profiles. However we had inadequate number of
narcolepsy patients without cataplexy after HLA-matching in this
study. Also, it could be interesting if IgG levels in CSF samples be
examined in future studies.
In conclusion, a significant decrease in the total IgG was
observed in a subgroup of narcolepsy patients. We also found IgG
subclass alterations in narcolepsy, suggesting IgG3- and IgG4-
related abnormal IgG maturation in narcolepsy. The HLA-
DQB1*0602 allele contributes to the decrease in the serum total
IgG levels. The differences in the IgG profiles observed between
narcolepsy and idiopathic hypersomnia indicate the immunolog-
ical differences between these two conditions.
Supporting Information
Figure S1 Influence of smoking for total IgG level (mg/ml).
Subjects who smoke more than one cigarette per day are included
Figure 6. Serum IgG4 level. Definitions of dots, dotted lines, horizontal lines, and squares are provided in the legend for Figure 2.
doi:10.1371/journal.pone.0009555.g006
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9555in smoking group. Horizontal lines and squares indicate the mean
6 SD. Numbers in graph indicate subject numbers in each group
(female number is in parentheses). *P,0.05 vs non-smoking
controls negative for HLA-DQB1*0602 (p values are as follows;
smoking controls negative for HLA-DQB1*0602; p=0.012,
smoking controls positive for HLA-DQB1*0602; p=0.005,
smoking or non-smoking narcolepsy; p,0.0001). +P,0.005 vs
IHS (p values are as follows; smoking controls negative for HLA;
p,0.0005, smoking or non-smoking HLA-positive controls;
p,0.005 and p,0.005, smoking or non-smoking narcolepsy;
p,0.00001).
Found at: doi:10.1371/journal.pone.0009555.s001 (0.03 MB PPT)
Acknowledgments
We thank Ms. Junko Watanabe (Neuropsychiatric Research Institute,
Japan) for clinical coordination and Ms. Miyuki Fukazawa (Tokyo Institute
of Psychiatry) for the processing of blood samples.
Author Contributions
Conceived and designed the experiments: ST. Performed the experiments:
ST. Analyzed the data: ST. Contributed reagents/materials/analysis tools:
ST MH. Wrote the paper: ST MH.
References
1. American Academy of Sleep Medicine (2005) International Classification of
SLEEP DISORDERS, 2
nd ed, Diagnostic & Coding Manual: Westchester,
Illinois.
2. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, et al. (2001) Complex HLA-DR
and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.
Am J Hum Genet 68: 686–699.
3. Black JL, 3rd, Silber MH, Krahn LE, Fredrickson PA, Pankratz VS, et al. (2005)
Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 28:
427–431.
4. Black JL, 3rd, Silber MH, Krahn LE, Avula RK, Walker DL, et al. (2005)
Studies of Humoral Immunity to Preprohypocretin in Human Leukocyte
Antigen DQB1*0602-Positive Narcoleptic Subjects with Cataplexy. Biol
Psychiatry 58: 504–509.
5. Tanaka S, Honda Y, Inoue Y, Honda M (2006) Detection of autoantibodies
against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in
narcolepsy. Sleep 29: 633–638.
6. Overeem S, Verschuuren JJ, Fronczek R, Schreurs L, den Hertog H, et al.
(2006) Immunohistochemical screening for autoantibodies against lateral
hypothalamic neurons in human narcolepsy. J Neuroimmunol 174: 187–191.
7. Martinez-Rodriguez JE, Sabater L, Graus F, Iranzo A, Santamaria J (2007)
Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy.
Sleep 30: 27–28.
8. Knudsen S, Mikkelsen JD, Jennum P (2007) Antibodies in narcolepsy-cataplexy
patient serum bind to rat hypocretin neurons. Neuroreport 18: 77–79.
9. Honda M, Eriksson KS, Zhang S, Tanaka S, Lin L, et al. (2009) IGFBP3
colocalizes with and regulates hypocretin (orexin). PLoS ONE 4: e4254.
10. Tanaka S, Kawashima M, Honda M (2009) Absence of anti-aquaporin-4
antibodies in narcolepsy. Sleep and Biological Rhythms 7: 66–70.
11. Jackson MW, Reed JH, Smith AJ, Gordon TP (2008) An autoantibody in
narcolepsy disrupts colonic migrating motor complexes. J Neurosci 28:
13303–13309.
12. Valko PO, Khatami R, Baumann CR, Bassetti CL (2008) No persistent effect of
intravenous immunoglobulins in patients with narcolepsy with cataplexy.
J Neurol 255: 1900–1903.
13. Dauvilliers Y (2006) Follow-up of four narcolepsy patients treated with
intravenous immunoglobulins. Ann Neurol 60: 153.
14. Ichihara K, Itoh Y, Lam CW, Poon PM, Kim JH, et al. (2008) Sources of
variation of commonly measured serum analytes in 6 Asian cities and
consideration of common reference intervals. Clin Chem 54: 356–365.
15. Oxelius VA (1984) Immunoglobulin G (IgG) subclasses and human disease.
Am J Med 76: 7–18.
16. French MA, Harrison G (1984) Serum IgG subclass concentrations in healthy
adults: a study using monoclonal antisera. Clin Exp Immunol 56: 473–475.
17. Ton TG, Longstreth WT, Jr., Koepsell T (2009) Active and passive smoking and
risk of narcolepsy in people with HLA DQB1*0602: a population-based case-
control study. Neuroepidemiology 32: 114–121.
18. Zager A, Andersen ML, Ruiz FS, Antunes IB, Tufik S (2007) Effects of acute
and chronic sleep loss on immune modulation of rats. Am J Physiol Regul Integr
Comp Physiol 293: R504–509.
19. Hui L, Hua F, Diandong H, Hong Y (2007) Effects of sleep and sleep
deprivation on immunoglobulins and complement in humans. Brain Behav
Immun 21: 308–310.
20. Dhabhar FS (2002) Stress-induced augmentation of immune function–the role of
stress hormones, leukocyte trafficking, and cytokines. Brain Behav Immun 16:
785–798.
21. Zalcman S, Henderson N, Richter M, Anisman H (1991) Age-related
enhancement and suppression of a T-cell-dependent antibody response
following stressor exposure. Behav Neurosci 105: 669–676.
22. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, et al. (2009) Elevated anti-
streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32:
979–983.
23. Vernet C, Arnulf I (2009) Idiopathic hypersomnia with and without long sleep
time: a controlled series of 75 patients. Sleep 32: 753–759.
24. Lange T, Dimitrov S, Fehm HL, Westermann J, Born J (2006) Shift of monocyte
function toward cellular immunity during sleep. Arch Intern Med 166:
1695–1700.
25. Carlander B, Vincent T, Le Floch A, Pageot N, Camu W, et al. (2008)
Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes.
J Neurol Neurosurg Psychiatry 79: 333–334.
26. Nozaki H, Shimohata T, Kanbayashi T, Sagawa Y, Katada SI, et al. (2008) A
patient with anti-aquaporin 4 antibody who presented with recurrent
hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic
lesions. Sleep Med 10: 253–255.
27. Baba T, Nakashima I, Kanbayashi T, Konno M, Takahashi T, et al. (2009)
Narcolepsy as an initial manifestation of neuromyelitis optica with anti-
aquaporin-4 antibody. J Neurol 256: 287–288.
28. Mignot E, Bell RA, Rattazzi C, Lovett M, Grumet FC, et al. (1994) An
immunoglobulin switchlike sequence is linked with canine narcolepsy. Sleep 17:
S68–76.
29. Singh SM, George CF, Ott RN, Rattazzi C, Guilleminault C, et al. (1996) IgH
(mu-switch and gamma-1) region restriction fragment length polymorphism in
human narcolepsy. J Clin Immunol 16: 208–215.
30. Bassetti C, Aldrich MS (1997) Idiopathic hypersomnia. A series of 42 patients.
Brain 120(Pt 8): 1423–1435.
31. Billiard M, Merle C, Carlander B, Ondze B, Alvarez D, et al. (1998) Idiopathic
hypersomnia. Psychiatry Clin Neurosci 52: 125–129.
32. Honda Y, Honda M (1998) [Idiopathic hypersomnia–review of literatures and
clinical experiences on 16 Japanese cases]. Nippon Rinsho 56: 371–375.
33. Cejka J, Mood DW, Kim CS (1974) Immunoglobulin concentrations in sera of
normal children: quantitation against an international reference preparation.
Clin Chem 20: 656–659.
IgG Abnormality in Hypersomnia
PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9555